Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
177Lu-DOTATATE versus 177Lu-EDTMP versus cocktail/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour: can semiquantitative comparison of 68Ga-DOTATATE and 18F-fluoride PET-CT aid in personalized treatment decision making in selecting the best therapeutic option?
Basu S, Ranade R, Thapa P. Basu S, et al. Among authors: thapa p. Nucl Med Commun. 2016 Jan;37(1):100-2. doi: 10.1097/MNM.0000000000000397. Nucl Med Commun. 2016. PMID: 26587985 No abstract available.
Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: developing a personalized model.
Basu S, Ranade R, Thapa P. Basu S, et al. Among authors: thapa p. Nucl Med Commun. 2015 Aug;36(8):766-74. doi: 10.1097/MNM.0000000000000321. Nucl Med Commun. 2015. PMID: 25920048 Review.
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep, Thapa P, Wanage G, Tervankar S, Kaisar S, Ranade R, Basu S, Das T, Banerjee S. Kamaldeep, et al. Among authors: thapa p. Nucl Med Commun. 2021 Oct 1;42(10):1076-1084. doi: 10.1097/MNM.0000000000001434. Nucl Med Commun. 2021. PMID: 34528928
653 results